Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$734M |
| 2 |
Boeing
BA
|
+$493M |
| 3 |
Pfizer
PFE
|
+$478M |
| 4 |
UnitedHealth
UNH
|
+$440M |
| 5 |
Honeywell
HON
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.05B |
| 2 |
Advanced Micro Devices
AMD
|
+$447M |
| 3 |
TSMC
TSM
|
+$441M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 5 |
ExxonMobil
XOM
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.34% |
| 2 | Technology | 16.84% |
| 3 | Consumer Discretionary | 12.66% |
| 4 | Industrials | 10.11% |
| 5 | Consumer Staples | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TDCX
2926
DELISTED
TDCX Inc. American Depositary Shares, each representing one Class A ordinary share
TDCX
| $461K | ﹤0.01% |
51,818
-36,913
| -42% | -$446K |
|
2927
Corvus Pharmaceuticals
CRVS
$1.12B
| $460K | ﹤0.01% |
506,032
-142,600
| -22% | -$111K |
|
2928
Bogota Financial
BSBK
$116M
| $459K | ﹤0.01% |
45,931
+4,731
| +11% | +$52.9K |
|
|
HEXO
2929
DELISTED
HEXO Corp. Common Shares
HEXO
| $458K | ﹤0.01% |
341,613
+97,300
| +40% | +$142K |
|
2930
Genasys
GNSS
$76.1M
| $457K | ﹤0.01% |
154,936
-1,000
| -0.6% | -$3.57K |
|
|
EEX
2931
DELISTED
Emerald Holding
EEX
| $456K | ﹤0.01% |
122,672
+6,615
| +6% | +$24.7K |
|
2932
Redwire
RDW
$2.06B
| $456K | ﹤0.01% |
150,595
+99,395
| +194% | +$293K |
|
2933
Vanguard Consumer Discretionary ETF
VCR
$6.15B
| $455K | ﹤0.01% |
1,800
-4,200
| -70% | -$1.02M |
|
2934
Bausch + Lomb
BLCO
$6.04B
| $454K | ﹤0.01% |
+26,100
| New | +$442K |
|
2935
Nuvation Bio
NUVB
$2.2B
| $453K | ﹤0.01% |
273,100
+128,900
| +89% | +$261K |
|
|
SII
2936
Sprott
SII
$2.66B
| $452K | ﹤0.01% |
+12,400
| New | +$464K |
|
2937
Vanguard S&P Small-Cap 600 Value ETF
VIOV
$1.85B
| $452K | ﹤0.01% |
5,600
+3,000
| +115% | +$253K |
|
|
NUVL
2938
DELISTED
Nuvalent
NUVL
| $451K | ﹤0.01% |
17,300
+1,000
| +6% | +$29.6K |
|
2939
Absci
ABSI
$1.32B
| $450K | ﹤0.01% |
256,900
+194,993
| +315% | +$472K |
|
2940
Fidelity MSCI Health Care Index ETF
FHLC
$3.28B
| $449K | ﹤0.01% |
7,300
-4,400
| -38% | -$273K |
|
|
EXAI
2941
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $448K | ﹤0.01% |
84,600
+57,800
| +216% | +$392K |
|
|
SA
2942
Seabridge Gold
SA
$2.78B
| $446K | ﹤0.01% |
34,600
-110,900
| -76% | -$1.37M |
|
2943
UroGen Pharma
URGN
$1.86B
| $444K | ﹤0.01% |
48,000
+4,700
| +11% | +$43.3K |
|
2944
Bristow Group
VTOL
$1.34B
| $444K | ﹤0.01% |
19,800
+8,700
| +78% | +$231K |
|
|
SURF
2945
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $444K | ﹤0.01% |
635,000
-79,155
| -11% | -$64.1K |
|
2946
BGSF Inc
BGSF
$59.5M
| $442K | ﹤0.01% |
+41,500
| New | +$579K |
|
2947
EuroDry
EDRY
$76.6M
| $442K | ﹤0.01% |
26,700
-1,000
| -4% | -$17K |
|
2948
Cognyte Software
CGNT
$659M
| $440K | ﹤0.01% |
129,700
+3,400
| +3% | +$12.3K |
|
2949
Dimensional US Core Equity Market ETF
DFAU
$12.4B
| $440K | ﹤0.01% |
15,300
-53,900
| -78% | -$1.52M |
|
2950
Trevi Therapeutics
TRVI
$2.59B
| $439K | ﹤0.01% |
237,400
-80,600
| -25% | -$182K |
|
Similar funds
Renaissance Technologies's Q1 2023 Portfolio in Review
As of Q1 2023, Renaissance Technologies held 4,600 positions worth $75.4B, up 3.1% from $73.1B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2023 filing shows 524 new, 1,665 increased, 1,689 reduced and 668 closed positions. Its largest new stake was Honeywell: 1,937,917 shares worth $349M. The largest sale was Apple, an estimated $1.05B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q1 2023 buy was Honeywell: 1,937,917 shares worth $349M.
- Renaissance Technologies added most to First Republic Bank in Q1 2023, an estimated $734M increase.
- Renaissance Technologies's biggest Q1 2023 reduction was Apple, cutting an estimated $1.05B.
- Renaissance Technologies fully exited Advanced Micro Devices in Q1 2023, selling an estimated $447M.
- Renaissance Technologies's ten largest holdings make up 11% of its $75.4B portfolio in Q1 2023.
- Renaissance Technologies opened 524 new positions and closed 668 in Q1 2023.
- Renaissance Technologies's portfolio value rose 3.1% quarter-over-quarter to $75.4B.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.